Artificial intelligence-based model for the recurrence of hepatocellular carcinoma after liver transplantation

被引:2
|
作者
Altaf, Abdullah [1 ,2 ]
Mustafa, Ahmed [3 ]
Dar, Abdullah [2 ]
Nazer, Rashid [4 ]
Riyaz, Shahzad [5 ]
Rana, Atif [4 ]
Bhatti, Abu Bakar Hafeez [2 ,6 ]
机构
[1] King Edward Med Univ, Lahore, Pakistan
[2] Shifa Int Hosp, Dept HPB & Liver Transplant Surg, Sector H-8-4,Pitras Bukhari Rd, Islamabad 44000, Pakistan
[3] Natl Univ Sci & Technol, Dept Robot & Artificial Intelligence, Islamabad, Pakistan
[4] Shifa Int Hosp, Dept Radiol, Islamabad, Pakistan
[5] Shifa Int Hosp, Dept Gastroenterol & Hepatol, Islamabad, Pakistan
[6] Shifa Tameer E Millat Univ, Dept Surg, Islamabad, Pakistan
关键词
SELECTION CRITERIA; EXPANSION;
D O I
10.1016/j.surg.2024.07.039
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Artificial intelligence-based models might improve patient selection for liver transplantation in hepatocellular carcinoma. The objective of the current study was to develop artificial intelligence-based deep learning models and determine the risk of recurrence after living donor liver transplantation for hepatocellular carcinoma. Methods: The study was a single-center retrospective cohort study. Patients who underwent living donor liver transplantation for hepatocellular carcinoma were divided into training and validation cohorts (n 1/4 192). The deep learning models were used to stratify patients in the training cohort into low- and highrisk groups, and 5-year recurrence-free survival was assessed in the validation cohort. Results: The median follow-up period was 59.1 (33.9-72.4) months. The artificial intelligence model (pretransplant factors) had an area under the curve of 0.86 in the training cohort and 0.71 in the validation cohort. The largest tumor diameter and alpha-fetoprotein level had the greatest Shapley Additive exPlanations values for recurrence (>0.4). The 5-year recurrence-free survival rates in the low- and highrisk groups were 92.6% and 45% (P < .001). In the second artificial intelligence model (pretransplant factors & thorn; grade), the area under the curve for the validation cohort was 0.77, with 5-year recurrence-free survival rates of 96% and 30% in the low- and high-risk groups (P < .001). None of the low-risk patients outside the Milan and University of California San Francisco Criteria had recurrence during follow-up. Conclusions: The artificial intelligence-based hepatocellular carcinoma transplant recurrence models might improve patient selection for liver transplantation. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:1500 / 1506
页数:7
相关论文
共 50 条
  • [31] Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
    Kim, Jong Man
    CLINICAL AND MOLECULAR HEPATOLOGY, 2021, 27 (04) : 562 - 563
  • [32] Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation
    Schlitt, HJ
    Neipp, M
    Weimann, A
    Oldhafer, KJ
    Schmoll, E
    Boeker, K
    Nashan, B
    Kubicka, S
    Maschek, H
    Tusch, G
    Raab, R
    Ringe, B
    Manns, MP
    Pichlmayr, R
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 324 - 331
  • [33] Effect of tacrolimus on recurrence of hepatocellular carcinoma after liver transplantation
    Vivarelli, Marco
    Cucchetti, Alessandro
    Dazzi, Alessandro
    La Barba, Giuliano
    Cescon, Matteo
    Del Gaudio, Massimo
    Lauro, Augusto
    Ravaioli, Matteo
    Grazi, Gian Luca
    Pinna, Antonio D.
    TRANSPLANT INTERNATIONAL, 2007, 20 : 33 - 34
  • [34] Diabetes Mellitus and Hepatocellular Carcinoma Recurrence after Liver Transplantation
    Ling, Qi
    Xu, Xiao
    Chen, Jun
    He, Zenglei
    Xie, Haiyang
    Zheng, Shusen
    LIVER TRANSPLANTATION, 2011, 17 (06) : S297 - S297
  • [35] Development of a deep learning model for predicting recurrence of hepatocellular carcinoma after liver transplantation
    Ko, Seung Hyoung
    Cao, Jie
    Yang, Yong-kang
    Xi, Zhi-feng
    Han, Hyun Wook
    Sha, Meng
    Xia, Qiang
    FRONTIERS IN MEDICINE, 2024, 11
  • [36] Establishment of a novel integrated model for prediction of hepatocellular carcinoma recurrence after liver transplantation
    Ng, K. T. P.
    Luo, R. B.
    Liu, J.
    Lam, L. Y. F.
    Yeung, O. W. H.
    Liu, H.
    Liu, X. B.
    Lo, C. M.
    Man, K.
    TRANSPLANTATION, 2019, 103 (08) : 68 - 69
  • [37] Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma
    Freise, CE
    Ferrell, L
    Liu, T
    Ascher, NL
    Roberts, JP
    TRANSPLANTATION, 1999, 67 (04) : 510 - 513
  • [38] TUMOR RECURRENCE PREDICTS HBV RECURRENCE AFTER LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA
    Kim, Seong Hoon
    Kim, Young-Kyu
    Lee, Seung Duk
    Han, Sung-Sik
    Park, Sang-Jae
    TRANSPLANT INTERNATIONAL, 2013, 26 : 293 - 293
  • [39] Recurrence of Hepatocellular Carcinoma after Liver Transplantation: Recurrence Characteristics and Risk Factors
    Li, Chuan
    Wen, Tian-Fu
    Liao, Zhi-Xue
    Yan, Lv-Nan
    Li, Bo
    Zeng, Yong
    Wang, Wen-Tiao
    Xu, Ming-Qing
    Yang, Jia-Ying
    Wei, Yong-Gang
    HEPATO-GASTROENTEROLOGY, 2010, 57 (99-100) : 567 - 570
  • [40] Salvage liver transplantation for hepatocellular carcinoma recurrence after primary liver resection
    Qu, Wei
    Zhu, Zhi-Jun
    Sun, Li-Ying
    Wei, Lin
    Liu, Ying
    Zeng, Zhi-Gui
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2015, 39 (01) : 93 - 97